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Abstract
Background: Hemoglobin is a rich source of biological peptides. As a byproduct and even wastewater of poultry-
slaughtering facilities, chicken blood is one of the most abundant source of hemoglobin.
Results: In this study, the chicken hemoglobin antimicrobial peptides (CHAP) were isolated and the antimicrobial
and bactericidal activities were tested by the agarose diffusion assay, minimum inhibitory concentration (MIC)
analysis, minimal bactericidal concentration (MBC) analysis, and time-dependent inhibitory and bactericidal assays.
The results demonstrated that CHAP had potent and rapid antimicrobial activity against 19 bacterial strains,
including 9 multidrug-resistant bacterial strains. Bacterial biofilm and NaCl permeability assays, transmission electron
microscopy (TEM) and scanning electron microscopy (SEM) were further performed to detect the mechanism of its
antimicrobial effect. Additionally, CHAP showed low hemolytic activity, embryo toxicity, and high stability in
different temperatures and animal plasma.
Conclusion: CHAP may have great potential for expanding production and development value in animal
medication, the breeding industry and environment protection.
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Background
Due to the widespread use and even abuse of conven-
tional antibiotics, antibiotic resistance is rampant all
over the world, which limits the lifespan of commercial
antibiotics and results in the urgent demand of new plat-
forms for efficient antibiotic discovery [1, 2].
As an essential part of innate immunity, antimicrobial
peptides (AMPs) have been receiving increasing atten-
tion because of their unique antimicrobial mechanism
against both Gram-positive and Gram-negative bacteria,
and even including some multidrug-resistant strains over
recent decades [3, 4]. Antimicrobial peptides are ubiqui-
tous in all living organisms. More than 5000 AMPs
(http://www.camp.bicnirrh.res.in/index.php) have been
identified and 2593 peptides have been derived naturally
(http://aps.unmc.edu/AP/main.php) since the discovery
of the lysozyme by Alexander Fleming in 1922 [5]. Al-
though substantial AMPs have been discovered over the
past decades, only a small part of them have been used
because of high costs and potential cytotoxicity [1, 6].
Hence, finding efficient, nontoxic and low-cost AMPs is
urgent in promoting AMPs’ practical applications.
The whole blood is a mixture of cells (erythrocytes,
leucocytes and platelets) and plasma (colloids and crys-
talloids), which delivers nourishment and oxygen to and
removes waste products from all parts of the body [7].
Components in blood, such as platelet concentrates [8],
defensins [3], leukocyte extracts [9], also play important
roles in antimicrobial host defense. Hemoglobin is the
main component of the erythrocyte [10]. Aside from the
basic function of transporting oxygen, hemoglobin has
been found as a source of various biological peptides
[11–13]. Many AMPs called hemocidins have been iso-
lated from hemoglobin cleavage in vivo [14] or from
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hemoglobin hydrolysis by chemical reagents, physical
methods, or enzymes in vitro [15, 16]. To date, the
hemocidins derived from human beings [17], bovines
[12], rabbits [18], swine [15], crocodiles [19], fish [20],
and shellfish [21] have been reported and most of them
are made up of 2 to 60 residues, characterized by a com-
mon random coil structural and broad-spectrum anti-
microbial activity [22–24]. As a byproduct and even one
of the major dissolved pollutants in slaughter house
wastewater [25], appropriate treatment of chicken blood
is of great benefit to both environmental protection and
economic development. However, hemocidins from
poultry have not been documented yet. In this study, the
hemocidins from chickens were isolated and their




All common chemical reagents and biological products
were of analytical grade from commercial sources.
Papain (2000 IU g−1) was purchased from Sigma Chemical
Co. (St. Louis, Mo, America).
Preparation of CHAP
The chicken hemoglobin antimicrobial peptides (CHAP)
were prepared as modified method described before
[26]. In brief, fresh chicken blood (Beijing Huadu Broiler
Corporations, Beijing, China) was collected with heparin
and then centrifuged with 2,000 × g at 4 °C for 10 min.
The upper liquid and white cells were removed and
washed with sterilized saline. The procedures described
above were repeated 3 times. The cells were frozen,
thawed, stirred and homogenized in deionized water
(pH 7.0) with papain (1:1,000 w/v) proteolysis at 70 °C
for 8 h. The digested suspensions were added with ice-
cold aqueous 5% acetic acid solution (1:1 v/v) and ex-
tracted overnight at 4 °C. After being centrifuged at
8,000 × g for 30 min at 4 °C, the suspensions were col-
lected as crude extracts, and the protein concentration
was detected by NanoDrop 2000 UV–vis Spectropho-
tometer (Thermo Fisher Scientific, Massachusetts,
America). The pH of the extracts was adjusted to 6.0
with sodium hydroxide. The crude extracts were loaded
onto 10 × 300 mm Sephadex G-100 column and eluted
by 0.2 mol L−1 sodium acetate buffer (pH 6.0) with the
speed of 12.0 mL cm−2 h -1. Each elution was analyzed
by agarose diffusion assay [27] with Escherichia coli
ATCC 25922 as the indicator organism. The fractions
with potent antibacterial activity were collected and de-
tected with Tricine SDS-PAGE [28] and then subjected
to mass spectrometry (Beijing Protein Innovation Co.,
Ltd., Beijing, China).
Bacterial strains and growth conditions
Staphylococcus aureus ATCC25923, Staphylococcus
aureus ATCC 29213, Staphylococcus albus ATCC01331,
Escherichia coli ATCC 25922, Escherichia coli O78,
Escherichia coli C83922, Escherichia coli C83901,
Pseudomonas aeruginosa ATCC27853, Pasteurellae galli-
narum C48-3 were purchased from the China Veterinary
Culture Collection Center (CVCC). Aeromonas hydro-
phila, Bacillus cereus and Escherichia coli were clinically
isolated from crucian carps, pigeon and equines respect-
ively by Laboratory of Veterinary Pathology and Public
Health of the College of Veterinary Medicine, China
Agricultural University. Staphylococcus aureus MR-L22,
MR-QD-CD10, Enterococcus faecalis 53A, 52A, 37 N
and Pseudomonas aeruginosa M140 and Escherichia coli
T50 were all multi-resistance strains of clinics, and ob-
tained from Beijing Key Laboratory of Detection Tech-
nology for Animal Food safety of the College of
Veterinary Medicine. All the above Gram-negative
strains were grown in Luria-Bertani (LB) agar and the
Gram-positive bacteria were grown in brain heart infu-
sion (BHI) agar.
Determination of antimicrobial and bactericidal activities
Agarose diffusion assay
The primary antibacterial activities of CHAP elution
(100 μg mL−1) were detected by modified agarose diffu-
sion assay as described before [27]. Briefly, the single
colony of each bacterial strain was grown in trypticase
soy broth (TSB, 30 g L−1) overnight at 37 °C under aer-
obic conditions. 2 × 108 CFU mL−1 bacteria culture of
each strain was added to warm (50–55 °C) sterile agarose
[1% agarose (low EEO, Sigma, St. Louis, MO), 0.03% nu-
trient broth, and 10 mM PBS buffer, pH 7.4] (1:100 v/v).
10 μL samples were added to 3 mm wells punched
by agar punch (BioRad Laboratories, Hercules,
Canda). 0.2 mol L−1 sodium acetate (solvent) and
20000 IU penicillin-streptomycin solution of the same
volume were added as negative and positive control,
respectively. After being incubated overnight at 37 °C,
the diameter of the each clean zone of growth inhib-
ition was measured as the antibacterial activity of
CHAP against different strains.
Minimum inhibitory concentration (MIC) analysis
A micro dilution assay was employed to determine MIC
according to the broth micro dilution guideline of Clin-
ical and Laboratory Standards Institute (CLSI) [29].
Briefly, 50 μL of twofold serial dilutions of CHAP (25 to
0.20 μg mL−1) was placed into wells of sterile 96-well
cell culture plates. The 50 μL of bacterial suspensions
(1 × 105 CFU mL−1) were added to the peptides. The
wells were added with 50 μL of Mueller- Hinto (MH)
broth and 50 μL of bacterial culture was treated as
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positive and negative control, respectively. After 24 h in-
cubation, the MICs were determined at 492 nm by spec-
trophotometer (Thermo Multiskan MK3, Thermo Fisher
Scientific, Massachusetts, America).
Time-dependent inhibitory assay
A 500 μL aliquot of CHAP with 2 ×MIC of the bacter-
ium was added respectively to 500 μL bacterial suspen-
sions (1 × 105 CFU mL−1) in the sterilized 1.5 mL tubes
as the treated groups. Bacteria treated with 500 μL solv-
ent (0.2 mol L−1 sodium acetate) were set as the control
groups. After being incubated for 30 min, 100 μL aliquot
of the suspensions were pipetted into to a sterilized
1.5 mL tube. After centrifugation at 1,000 × g for 5 min,
the supernatant was removed, and the pellet was resus-
pended in 100 μL MHB medium. Tenfold serially diluted
suspension was placed on agar plates and incubated at
37 °C until viable colonies could be seen and the
numbers of colony-forming units (CFU) were counted.
The inhibitory rate of each bacterium was calculated ac-
cording to the following formula: the inhibitory rate
= [(colonies of the treated group - colonies of the treated
group)/colonies of the control group] × 100%.
In order to further detect the process and speed of the
antimicrobial activity of CHAP, the time growth curves
and inhibitory rates of Escherichia coli ATCC 25922,
Staphylococcus aureus ATCC29213, Staphylococcus aur-
eus MR-L22, Enterococcus faecalis 52A, Pseudomonas
aeruginoda M140 and Escherichia coli T50 were
achieved after the treated suspensions were incubated
for 0, 5, 10, 30, 90 min respectively.
Minimal bactericidal concentration (MBC) analysis
The MBC values were determined in 96-well plates,
which was similar to the method of MIC. MBC values
were further confirmed by plating 100 μL samples of
each well with no visible turbidity onto the MHB
medium. The least concentration showing no visible
growth on the plates was considered as the MBC value.
Time-dependent bactericidal assay
The time depending bactericidal curves of Escherichia
coli ATCC 25922 were determined as the time-
dependent inhibitory assay mentioned above by adding
CHAP with concentration of its MBC value to the bac-
terial cultures grown to early and late exponential phase
as the reference [2].
In order to detect the bacteriolysis against bacteria in
stationary phase, 10 ml of bacterial culture (2 × 10 9
CFU mL−1) was treated with 10 ×MIC of CHAP. The
culture treated with solvent (0.2 mol L−1 sodium acetate)
was set as the control group. After 24 h incubation, 2 ml
of each culture was added to a glass tube and was photo-
graphed [2].
Bacterial biofilms assay
Crystal violet staining method was applied to detect
the effect of CHAP on the biofilm formation [30].
Briefly, Staphylococcus aureus ATCC29213 were cul-
tured in TSB overnight. 100 μL bacterial suspensions
(1 × 106 CFU mL−1) with 2 ×MIC, 1 ×MIC, 1/2 ×
MIC, 1/4 ×MIC, 1/8 ×MIC, 1/16 ×MIC of CHAP
were added to 96-well plates and the bacterial sus-
pensions with no CHAP and the sterilized TSB were
treated as control groups. After static culture at 37 °C
for 24 h or shake culture (50 rmp) at 37 °C for 72 h,
the contents were aspirated and the wells were
washed by 200 μL PBS for three times, methanol
fixed for 1 h and stained with 200 μL crystal violet
(5 g L−1) for 30 min. The wells were washed by run-
ning water and air dried. The plates were determined
at 600 nm by spectrophotometer.
NaCl permeability assay
The effect of CHAP on the NaCl permeability of bac-
teria was detected as modified protocol as follows [31].
100 μL of bacterial suspensions (1 × 106 CFU mL−1) with
1/2 ×MIC of CHAP were added to 96-well plates and
the bacterial suspensions with no CHAP as control.
100 μL of NaCl solutions with different concentrations
(80, 100, 120, 140, 160, 180, 200 g L−1) were added into
each wells and incubated at 37 °C for 12 h. The bacterial
concentration of each well was determined by measuring
the optical density at 600 nm (OD600).
Electron microscopy observations
Both transmission electron microscopy (TEM) and
scanning electron microscopy (SEM) were conducted as
previously described [32–34]. Briefly, Escherichia coli
ATCC 25922 and Staphylococcus aureus ATCC29213
were cultured overnight, 107 CFU ml−1 bacteria were in-
cubated with 1 ×MIC of CHAP or diluents of the same
volume at 37 °C for 30 min. All the samples were fixed
and proceeded for the TEM and SEM respectively.
Hemolytic assay and embryotoxicity assay
The hemolytic activity was evaluated as previously de-
scribed [35]. 4% (vol/vol) fresh chicken erythrocyte sus-
pensions were added to a 96-well plate and incubated
with CHAP at 360, 180, 90, 45, 22.5, 11.25 μg mL−1 indi-
vidually at 37 °C for 1 h. Wells treated with PBS and
0.1% Triton X-100 of the same volume were taken as 0
and 100% hemolysis. The wells were determined by
measuring the optical density at 492 nm (OD492).
The embryotoxicity of CHAP was detected as the fol-
lowing measures. The 10-days-old-chicken embryos
were randomly divided into 5 groups, each of 10 eggs,
0.2 mL of CHAP of 1 ×MIC, 2 ×MIC, 4 ×MIC, 6 ×MIC
dose against Escherichia coli ATCC25922 were injected
Hu et al. BMC Microbiology  (2016) 16:287 Page 3 of 10
into the chorio-allantoic cavity, and embryos treated
with the same volume of solvent (0.2 mol L−1 sodium
acetate) were used as controls. The eggs were put in a
hatching machine and hatchability and weight of the
eggs were observed regularly until hatching.
Stability in different temperatures and in 50% plasma
CHAP (100 μg mL−1) was treated with different temper-
atures varying from 30 °C, 40 °C, 50 °C, 60 °C, 70 °C,
80 °C, 90 °C, 100 °C, 121 °C for 30 min. The antimicro-
bial activities of these treated aliquots were determined
with agarose diffusion assay and were compared with
CHAP stored in 4 °C.
The stability of CHAP in 50% plasma was evaluated as
previously described [29] with some modifications.
Briefly, the plasma of chicken and rabbit was determined
with no antimicrobial activity before the test. Then
640 μg ml−1 CHAP was diluted 1:1 in fresh chicken and
rabbit plasma and pre-incubated at 37 °C for 0, 3, and
6 h respectively. After incubation, the antimicrobial ac-
tivity of each sample was determined by agarose diffu-
sion assay. The effect of CHAP diluted by its solvent
was regarded as the 100%, and the effect of the treated
samples was demonstrated as percentages.
Statistical Analysis
Experiments were conducted with biological replicates
and experimental data were expressed as mean ± stand-
ard deviation of at least three determinations and ana-
lyzed by one-way ANOVA using SPSS 20.0 (SPSS Inc.,
Cary, NC, USA). Differences were considered to be sta-
tistically significant at P < 0.05 or P < 0.01.
Results
Preparation of CHAP
The crude extracts of CHAP were light yellow and the
protein concentration was adjusted to 5 mg ml−1 before
loading on the Sephadex G-100 column. There were two
main peaks after the elution of Sephadex G-100 gelatin
(Fig. 1a) and the tubes from 9 to 16 in the left half of the
second peak showed potent antimicrobial activity
(Fig. 1b). Detected by Tricine SDS –PAGE, the collected
CHAP showed band around 3.3 KDa (Fig. 1c). This band
was further analyzed and peptides of gallus hemoglobin
subunit alpha were confirmed by mass spectrum (see
Additional file 1).
Determination of antimicrobial and bactericidal activity
Antimicrobial effect of CHAP
The results of antibacterial activity of CHAP detected
via agarose diffusion assay, MIC assay and inhibitory rate
assay are shown in the columns 2–4 in Table 1.These re-
sults demonstrated that CHAP performed potent anti-
microbial activities against both Gram-negative bacteria
and Gram-positive bacteria, including 9 multidrug-
resistant strains.
The time-dependent growth inhibitory activities of
CHAP are shown in Fig. 2a-d. The results showed that
CHAP not only significantly inhibited the growth of
standard strains (P < 0.05), but also effectively inhibited
the multi-resistant ones (P < 0.05) in 10 min (Fig. 2a and
b). The inhibitory rates of all six strains reached 100% in
90 min (Fig. 2c and d). Although there were different
growth inhibitory curves, CHAP showed more than 50%
inhibitory rate against all six strains in 10 min.
Bactericidal effect of CHAP
The values of MBC are shown in column 5 of Table 1.
By analyzing the values, most bacteria were killed by
CHAP at concentrations ranging from 5 μg mL−1 to
80 μg mL−1. However, 7 strains showed no obvious bac-
tericidal effect with the maximum concentration of
160 μg mL−1. The time-dependent bactericidal curves in
Fig. 2e and f further revealed that the significant bacteri-
cidal effect of CHAP on both the bacteria grown to early
and late exponential phases from 10–240 min (P < 0.01).
Fig. 1 Preparation of CHAP. a Sephadex G-100 gelatin separation of the extract from chicken blood. b Antibacterial activity detection of elution
of Sephadex G-100 gelatin by agarose diffusion assay against Escherichia coli ATCC25922. c Tricine–SDS-PAGE of the interested elution and the
band was around 3.3 KDa (arrow)
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Especially the early exponential phase bacteria, they were
killed completely in only 10 min. The bacteria in station-
ary phase resulted in lysis after being treated with CHAP
for 24 h (Fig. 3a).
Bacterial biofilms assay
The formation of biofilms of Staphylococcus aureus
ATCC29213 was decreased with the increase of the con-
centration of CHAP (Fig. 3b). The 2 ×MIC, 1 ×MIC, 1/
2 ×MIC, 1/4 ×MIC, 1/8 ×MIC of CHAP could inhibited
the formation of biofilms (P < 0.01) in 24 h and 2 ×MIC,
1 ×MIC, 1/2 ×MIC, 1/4 ×MIC of CHAP could signifi-
cantly decrease the formation of biofilms (P < 0.01) in
72 h. Remarkably, in the 2 × MIC and 1 × MIC groups,
there were almost no biofilm formation.
NaCl permeability assay
As shown in Fig. 3c and d, the values of OD600 of Escheri-
chia coli ATCC 25922 and Staphylococcus aureus
ATCC29213 cultures decreased with the increased concen-
tration of NaCl solution and reached to their minimum
values at concentration above 160 g L−1 and above 140 g L
−1, respectively. By adding CHAP, the value of OD600 in both
Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC29213 groups decreased to the lowest value at con-
centration of NaCl above 120 g L−1.
Electron microscopy observations
The morphology of the Escherichia coli ATCC 25922
and Staphylococcus aureus ATCC29213 investigated by
SEM is shown in the Fig. 3. Compared to the smooth,
straight and unbroken surface of the control cells (Fig. 4a
and c), the strains treated with CHAP for 30 min ap-
peared severely damaged (Fig. 3b and d). The TEM im-
ages further demonstrated that the bacterial surfaces
were damaged by the effect of CHAP (Fig. 5a and c)
compared with the control group (Fig. 4b and d).
Hemolytic assay and embryotoxicity assay
The hemolysis of CHAP was 38.9% at the concentration
of 360 μg mL−1 which was more than 50 times higher
than the MIC values for all the detected bacteria (see
Additional file 2). And the embryotoxicity assay showed
that even CHAP of 6 ×MIC dose against Escherichia coli
ATCC25922 did not induce toxicity toward chicken em-
bryos, that is, there was no dead or significant decrease
of body weight compared to the control group (P > 0.05)
(see Additional file 3).
Table 1 Antibacterial activity and bactericidal activity of Chicken hemoglobin fragment peptides
Strains D (mm) MIC (μg mL−1) IR (%) MBC (μg mL−1)
Gram-negative bacteria
Escherichia coli ATCC 25922 24.5 6.25 83.00 80
Escherichia coli C83901 18 12.5 66.53 80
Escherichia coli C83922, 20 6.25 55.24 80
Escherichia coli O78 18 6.25 47.83 80
Aeromonas hydrophila(crucian carp) 13 3.13 52.05 >160
Pseudomonas aeruginosa ATCC27853 15 3.13 52.94 80
Pasteurellae gallinarum C48-3 12 3.13 63.63 80
MR- Escherichia coli(equine) 33.5 6.25 62.73 80
MR- Pseudomonas aeruginosa M140 19 1.56 85.56 5
MR- Escherichia coli T50(swine) 11 6.25 89.92 80
Gram-positive bacteria
Staphylococcus aureus ATCC25923 27 3.13 50.00 >160
Staphylococcus aureus ATCC 29213 21 3.13 94.26 5
Staphylococcus albus ATCC01331 14.5 1.56 73.36 40
MR-Bacillus cereus (pigeon) 13.5 3.13 73.36 20
MR-Staphylococcus aureus L22(swine) 15.5 6.25 88.6 >160
MR-Staphylococcus aureus QD-CD10 (swine) 15.5 6.25 56.93 >160
MR-Enterococcus faecalis 53A(pet) 22 1.56 91.10 >160
MR-Enterococcus faecalis 52A(pet) 13.5 6.25 35.00 >160
MR-Enterococcus faecalis 37 N(pet) 29 3.13 55.00 >160
MR multidrug resistance (in bold), D diameter of inhibition zone, MIC minimum inhibitory concentration, IR inhibitory rate in 30 min, MBC minimal
bactericidal concentration
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Fig. 3 a Bacteriolysis analysis. Bacteria in stationary phase treated with CHAP resulted in lysis with the solvent as control. b The inhibitory effect
of CHAP on bacterial biofilm for 24 h and 72 h. c-d The effect of CHAP on NaCl permeability of Escherichia coli ATCC 25922 and Staphylococcus
aureus ATCC29213
Fig. 2 a-b Time-dependent inhibitory curves of bacteria treated with CHAP and the bacteria treated with the solvent as control. a Gram-negative
bacteria. b Gram-positive bacteria. c-d Time-dependent growth inhibitory rate curves of bacteria treated with CHAP and the bacteria treated with
the solvent as control. c Gram-positive bacteria. d Gram-positive bacteria. e-f Time dependent bactericidal curves of Escherichia coli ATCC 25922
treated with CHAP and the bacteria treated with the solvent as control. e At early exponential phase. f At late exponential phase
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Stability in different temperatures and in 50% plasma
The antimicrobial activity of CHAP did not decrease in
different temperatures even when it was treated in 121 °C
for 30 min compared with CHAP stored in 4 °C (P > 0.05)
(Fig. 6a). It well proved that CHAP was capable of stability
in various temperatures.
Compared with CHAP diluted in the solvent, the anti-
microbial activity of CHAP showed no change in the
treatment of chicken plasma and a slight but no signifi-
cant decrease in treatment of rabbit plasma (P >0.05)
(Fig. 6b), which demonstrated that CHAP was of well
stability in the plasma.
Discussion
Since the first anti-Streptococcus peptide was identified
from the cow’s milk [36], the enzyme strategy of isolat-
ing AMPs on a large scale has been a feasible method as
Bolscher postulated [37]. Our lab isolated the peptides
from the hemoglobin of chickens by using a simple and
practical way and studied the antimicrobial activities
against 19 bacterial strains, including 9 multidrug-
resistant bacteria. At the same time, the properties such
as hemolytic activity, embryotoxicity and stability in dif-
ferent temperatures and plasma were detected, which
laid a foundation for its further employment in agricul-
tural production, public health and medication.
Antibiotics have been helping humans to fight against
hazardous infections since Alexander Fleming discov-
ered the first antibiotic, penicillin, in 1928 [38]. However,
resistance to most antibiotics was discovered shortly
after their applications. For example, penicillin resistance
arose in 1946 just one year after its introduction to
clinics [1]. The main target of most AMPs is cell mem-
brane and there are several models for explaining the
process such as barrel-stave pore model, thoroidal pore
model and carpet model [3, 29, 39], and it tends to be
difficult for bacteria to totally change this basic structure
to resist the effect of AMPs [3]. Given the unique anti-
microbial mechanism of AMPs, it was not surprising
that most AMPs induced little or no resistance [40, 41].
Although there are reports and doubts about the resist-
ance of some peptides [41, 42], there is no report about
the natural ones so far, which means the development of
natural AMPs is high in potential.
In our study, both the antimicrobial and bactericide re-
sults showed that CHAP was capable of strong and rapid ac-
tivities against various bacteria and even some multi-
resistant strains, implying its wider utility in the prevention
and treatment of infectious agents, which was similar with
the hemosidins reported before [16, 17]. By specifically
analyzing the results above, there was no obvious difference
between the antibacterial activity against Gram-negative
bacteria and Gram-positive bacteria, even between the
Fig. 4 The morphology of Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC29213 were investigated by scanning electron microscopy. a-b The
control group. c-d The Escherichia coli ATCC 25922 treated with CHAP. Viscous substances were adhering to almost all CHAP treated cells, which got large
number of bacteria together (arrowheads); Some bacteria showed variable length, rough cell surfaces or globular protrusions on their surfaces, and even
appeared to collapse (arrows)
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standard strains and the multi-resistant strains, sug-
gesting that the target of CHAP is the common com-
ponent of bacteria such as the cell membrane like
most AMPs reported before [29, 43]. The biofilm and
the NaCl permeability results showed that CHAP
could inhibit the formation of bacterial biofilms and
change the permeability of some Gram-negative
bacteria and Gram-positive bacteria to some extent.
With the confirmation of the mechanism of most
AMPs, the EM observations further revealed that
CHAP could accumulate copious pathogens nearby
and punch through their cell surfaces swiftly [29, 32].
Fig. 5 The morphology of Escherichia coli ATCC 25922 Staphylococcus aureus ATCC29213 were investigated by transmission electron microscopy.
a-b The control group. c-d The Escherichia coli ATCC 25922 treated with CHAP. Most of the bacteria were translucent and pores were evident on
walls especially at the two terminals of each cell (arrowheads). There was some intracellular substance released from many bacteria (arrows).
Fig. 6 The stability of CHAP. a The stability of the CHAP in different temperatures. b The stability of the CHAP in chicken and rabbit plasma
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However the specific mechanism needs to be further
investigated.
As a double-edged sword, the unique mechanism of tar-
geting cell membranes could also lead to the low selection
of some AMPs [3]. Hence, toxicity especially hemolysis
and safety problems, are constantly an obstacle to their
final applications [1, 40, 44]. According to our study,
CHAP demonstrated low hemolysis and embryotoxicity
even at rather high concentrations, which further implied
that there was relative high selectivity of CHAP between
eukaryote cells and prokaryote cells.
Good stability also plays an important role in the ap-
plication of any biological product. As for the AMPs, the
substances such as ions and proteolytic enzymes in the
serum may reduce their biological ability to a large ex-
tent [29, 45]. In this study, CHAP kept high antimicro-
bial activity in two kinds of animal serum and different
temperatures, suggesting its convenient application,
transportation and storage.
Conclusions
In summary, this study firstly reported a practical method
of isolating chicken hemosidins (CHAP) from the bypro-
duct and even the pollutant of chicken-slaughtering indus-
tries. CHAP has an attractive antimicrobial and bactericidal
ability with low hemolysis, low or none in toxicity and good
temperature resistance and high stability in serum, which
well accounts for their potential of expanding production
and high development value in animal medication, breeding
industry and environment protection.
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